Engflag

Celol-XT

Quick links to important sections

Celol-XT

Celol-XT_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Celol-XT

Quick Facts

Property Description
Active Ingredients Calcitriol, Elemental Calcium, Soy Isoflavones
Form Soft Gelatin Capsules
Pharmacological Class Mineral and Vitamin Supplement, Bone Mineral Density Regulator
General Purpose Bone Health Support and Mineral Regulation
Origin Mixed (Synthetic and Natural)

What Type of Medicine is Celol-XT? (Identity and Class)

Celol-XT is a specialized pharmaceutical preparation classified primarily as a Mineral and Vitamin Supplement and a Bone mineral density regulator. This multi-ingredient formulation is a Combination therapy typically supplied as Soft gelatin capsules for Oral administration. Its components stem from both Synthetic origins (Calcitriol) and Natural sources (Elemental Calcium and Soy Isoflavones).

Calcitriol is the metabolically active form of Vitamin D indicated for the management of various conditions related to calcium and bone metabolism. This composite structure is key to the product's function.

What are the Active Ingredients in Celol-XT? (Composition and Uniqueness)

The formula’s efficacy relies on three distinct Active ingredients / Chemical substances: Calcitriol, Elemental Calcium, and Soy Isoflavones (Phytoestrogens). Calcitriol ensures efficient calcium absorption, while Elemental Calcium provides the necessary mineral substrate for skeletal structure.

Crucially, the Soy Isoflavones component, which includes compounds like Daidzein and Genistein, differentiates this product. These Phytoestrogens exhibit effects relevant to supporting bone density, particularly in patient groups like Post-menopausal women seeking to maintain Bone mineral density.

What is the General Purpose of Celol-XT? (Core Benefit)

The general purpose of Celol-XT is to provide comprehensive support for Bone health support by resolving deficiencies in key micronutrients. The medicine’s design ensures robust Calcium absorption enhancement through the Calcitriol component, alongside supplying the Elemental Calcium required for direct Bone mineralization. This combination ensures both mineral availability and efficient uptake, offering a targeted strategy to maintain skeletal integrity.

Regulatory References

  1. MedlinePlus Drug Information, Calcitriol
  2. NIH PMC, Isoflavones and Bone

What side effects are possible with Celol-XT?

Possible side effects and safety information

The safety profile for Celol-XT is predominantly determined by the mineral-regulating components, Calcitriol and Elemental Calcium, with the primary risk documented in regulatory sources being hypercalcemia (excessive calcium levels in the blood).

This condition is classified as a Very Common (ge 10%) serious adverse reaction associated with the Calcitriol component, which establishes the central focus of the medicine’s official safety profile.

System-Organ Classes and Frequency

Adverse reactions are officially grouped by the physiological system affected. The Gastrointestinal System is commonly involved, with documented effects including nausea, abdominal pain, diarrhea, constipation, and dry mouth. The Renal and Urinary System is also a primary site, where hypercalciuria (excess calcium in urine) is listed as a Common (1-10%) adverse effect.

Headache is a Common side effect listed under Nervous System Disorders.

Serious Adverse Reactions and Time-Related Patterns

Serious adverse reactions, often linked to unmanaged or prolonged hypercalcemia, include nephrocalcinosis (calcification of the kidneys), ectopic calcification in soft tissues, and the potential for cardiac arrhythmias. Regulatory documentation explicitly distinguishes between Early Signs of excessive intake, such as weakness and muscle pain, and Late Signs like polyuria (increased urination) and weight loss, indicating exposure-related patterns.

Population-Specific Safety Constraints

The medicine is officially Contraindicated in individuals with pre-existing conditions of hypercalcemia or evidence of Vitamin D toxicity. Safety information requires specific monitoring of the serum calcium-phosphate product to prevent mineral deposition in soft tissues. Cautious use is officially advised for older adults and patients with renal impairment, reflecting the greater likelihood of reduced organ function in these groups.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Celol-XT is defined by the risk of hypercalcemia (elevated calcium in the blood) due to its Calcitriol and Elemental Calcium components. Overdose is associated with Vitamin D intoxication leading to this metabolic imbalance.

Classification Aspect Official Regulatory Statement
Documented Overdose Manifestations Early signs include weakness, headache, dry mouth, nausea, vomiting, metallic taste, and constipation. Late manifestations may include polyuria, polydipsia, and severe fatigue.
Severe Outcomes The regulatory context notes potential for life-threatening events, including cardiac arrhythmias (especially in patients taking digitalis) and the development of irreversible kidney damage, such as nephrocalcinosis.
Emergency Response Statement The product must be discontinued immediately upon suspicion of overdose or onset of hypercalcemia symptoms.
When to Seek Urgent Help Immediate medical attention or contact with emergency services is required for persistent or progressive early symptoms, or if severe manifestations such as collapse or seizure are observed.

Management is strictly symptomatic and supportive, as no specific antidote is known for Calcitriol intoxication. Treatment procedures involve steps to enhance calcium excretion and require continuous monitoring of laboratory values, including serum calcium, serum creatinine, and urinary calcium excretion.

Therapeutic Uses of Celol-XT

Quick Facts

  • May address: Osteoporosis (weak and brittle bones) in postmenopausal women.
  • Supports: The maintenance of adequate calcium and Vitamin D levels.
  • Promotes: The maintenance of bone density.

Celol-XT is a formulation designed to assist in addressing certain nutritional deficiencies that can impact bone health. The preparation is indicated for supporting the management of postmenopausal osteoporosis, a condition characterized by bone loss that can increase the potential for fractures. Its components contribute to the absorption of calcium, which is an essential mineral for the formation and maintenance of bone tissue. By supporting appropriate calcium levels in the body, the formulation may help strengthen bones and reduce the risk of bone loss following menopause.

The inclusion of specific components also supports the normal functioning of muscles and aids in maintaining the body's mineral balance. The therapeutic application of Celol-XT centers on providing supportive nutritional elements as part of a comprehensive strategy for managing bone health in eligible individuals.

Celol-XT is used under the direction of a healthcare provider as part of a plan to help maintain bone density and support overall bone structure.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who can and cannot use Celol-XT?

Eligibility for Celol-XT is strictly defined by regulatory documents, which establish specific populations who may use the medicine and those who must not. Use is generally intended for post-menopausal women who do not have any contraindications.

Contraindications and Restrictions

Classification Population or Condition
Absolutely Contraindicated Patients with Hypercalcemia (high blood calcium levels) or existing Vitamin D toxicity; Hypersensitivity to any component.
Not Recommended Patients with a history of Estrogen-dependent Neoplasms (due to the Soy Isoflavones component); Pregnancy and Lactation.
Use Not Established Children and Adolescents (under 18 years of age) for this indication.
Use with Caution Patients with Moderate to Severe Renal Impairment or those taking Digitalis/Digoxin; Use in Older Adults due to potential decrease in organ function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Classification and Constraints

The primary interaction constraints for Celol-XT are driven by its Vitamin D component (Calcitriol) and the calcium content, which affect systemic calcium levels and the absorption of co-administered medicines. The regulatory profile is structured around avoiding or cautiously managing combinations that either elevate serum calcium or interfere with the drug's absorption.

Interaction Type Interacting Substance/Class Resulting Constraint or Effect
Additive Hypercalcemia Other Vitamin D Preparations (e.g., Ergocalciferol) Use is contraindicated to avoid severe elevation of calcium levels.
Pharmacodynamic Risk Cardiac Glycosides (e.g., Digoxin, Digitoxin) May increase the toxicity and effect of cardiac glycosides due to elevated calcium levels. Monitoring is required.
Pharmacokinetic Absorption Bile Acid Sequestrants (e.g., Cholestyramine) May reduce the absorption and effectiveness of the drug component. Administration separation is required.
Pharmacodynamic Risk Thiazide Diuretics (e.g., Furosemide, Bumetanide) Increases the risk of hypercalcemia. Careful monitoring of calcium is necessary.
Absorption Interference Antacids (containing calcium or magnesium) May interfere with the absorption of the drug components. A required separation of administration time is typically needed.
Non-Medicinal Alcohol Consumption of alcohol is advised to be avoided as it may reduce calcium absorption.

Mechanism of Action

Modulation of Cellular Stress Response

Celol-XT acts primarily by chemically modifying key cellular sensors, such as Heat Shock Factor 1 (HSF1), which activates the cell's natural Heat Shock Response (HSR) pathway. This mechanism upregulates protective proteins and antioxidant enzymes, thereby increasing the cell's capacity to manage proteotoxicity and oxidative stress.

Targeting Pro-inflammatory Signaling Hubs

The compound exerts an inhibitory influence on central immune regulatory pathways, including the NF-κB pathway and key members of the MAPK kinase family. By disrupting the activation sequence of these hubs, Celol-XT reduces the cell's ability to produce and release inflammatory mediators, resulting in a reduction of inflammatory mediator output in the body's systems.

Influencing Cell Proliferation and Viability

Celol-XT engages mechanisms that modulate cell cycle progression and survival signaling (e.g., PI3K/AKT). This action can inhibit the growth of hyperactive cell populations and, in certain contexts, promote programmed cell death (apoptosis), contributing to the modulation of cell proliferation rates within tissue microenvironments.

Dosage and Administration Information

How to Use Celol-XT: Official Administration Guidelines

Celol-XT is a combination formulation prescribed for long-term use, and its proper administration is governed by specific instructions outlined in product information. The guidance below defines the official, standardized protocol for taking the medicine.

Administration Scope

Parameter Instruction
Route of Administration Celol-XT is designed for oral use only, supplied as a soft gelatin capsule.
Standard Dosing Regimen The typical recommended regimen is one capsule taken once or twice daily, depending on the healthcare provider's determination and the specific product strength available in the region.
Dosing Adjustment Principle The dose must be carefully individualized and may require adjustment based on ongoing monitoring, consistent with the protocols for Calcitriol-containing products.
Timing in Relation to Meals The capsules may be administered with or without food.
Administration Procedure The capsule should be swallowed whole with water and must not be crushed or chewed.
Age-Group Rules Dosing is generally initiated cautiously and often at the lower end of the range for older adults (geriatrics). The product is not typically indicated for use in pediatric patients.

Official Use Conditions and Protocol

Special Conditions for Use:

Proper use is reliant upon the patient maintaining an adequate daily intake of calcium alongside the medication, which may necessitate additional dietary sources or supplemental calcium, as mandated by official Calcitriol usage protocols.

Missed Dose Instructions:

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to prevent taking two doses simultaneously.

Connection to the Overall Use Protocol:

These official instructions define Celol-XT as a simple, daily oral medication intended for sustained use. The protocol emphasizes a consistent dosing schedule and mandates that the therapy is correctly supported by ensuring the patient has the required baseline calcium intake, which is integral to the product's function as outlined in clinical documentation.

Recent Clinical Evidence

Research evidence / Overview of studies for Celol-XT

Evidence for use in Postmenopausal Bone Health Support

The evidence landscape primarily consists of Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews that have examined the combination of calcium, active Vitamin D (Calcitriol), and soy isoflavones. These studies focus on objective measures related to bone structure and metabolism. The research monitored objective measures related to bone metabolism by measuring Bone Mineral Density (BMD) at key skeletal sites like the spine and hip. Additionally, research describes patterns in Bone Turnover Markers (BTMs), which are biochemical measures used to understand bone remodeling activity.

The studies report patterns in objective measurements observed in the populations when compared to control groups that received placebo. Findings were mixed regarding the measured changes in BMD, with differences observed when comparing the results across various skeletal sites. Evidence contributes to understanding the measured patterns, but certainty remains low for a consistent finding across all populations.

Evidence in Specific Patient Groups

Studies have been conducted in the specified patient populations and have included Postmenopausal women categorized by various factors. Researchers explored how the measured outcomes may differ depending on the population's baseline characteristics, such as years since menopause and initial bone mineral content.

Subgroup analyses describe patterns where reported measurements may differ based on these baseline characteristics. For instance, some findings were observed in some studies only in women who were further removed from menopause. The results apply only to the populations studied, and Data for certain groups remain insufficient to draw broad, universal conclusions.

Long-term Studies and Durability of Effect

The majority of research exploring short-term symptom changes has been conducted over defined time intervals typically ranging from 6 months to 2 years, with some longer trials extending up to 3 years. Long-term effects are not yet well-characterized based on the existing research structure. Data regarding the durability of the effect remain limited.

Synthesis of Research Uncertainty and Gaps

The overall evidence quality varies across studies, which leads to inconsistent findings when integrating reports from different trials. A key limitation is the high heterogeneity present in the research, due to significant variability in the specific formulation and dosage of the Soy Isoflavone component being studied. Subgroup findings are uncertain until confirmed by more extensive, large-scale studies. The research provides context but not individual predictions, and research is ongoing.

Key Studies & References NIH PMC: Isoflavones and Bone

Frequently Asked Questions (FAQ)

Common questions about Celol-XT (FAQ)

Q: Does Celol-XT interfere with or cause problems when taken with alcohol?

Official product information suggests limiting or avoiding alcohol consumption while taking this medicine. The regulatory guidance notes that alcohol may interfere with the body's ability to absorb calcium, which is a key component of the medication. This reduced absorption can potentially decrease the medicine's overall effectiveness.

Q: What is the official protocol for disposing of unused or expired Celol-XT?

According to official regulatory guidance, any unused or expired medication must be disposed of in a way that follows your local and national pharmaceutical waste regulations. The medicine is generally advised not to be placed directly into household trash or flushed down the toilet. When take-back programs are unavailable, certain disposal methods, such as mixing with undesirable substances (e.g., coffee grounds or dirt) and placing in a sealed bag before trash, may be recommended.

Q: Is it safe to drive or operate machinery while taking this medicine?

Official product information states that it is unknown whether Celol-XT alters a person's ability to drive or operate machinery. Official information suggests that driving should only occur if you feel fully alert and capable after taking the medication. If any side effects or symptoms that affect your ability to concentrate or react occur, caution should be taken regarding driving or operating heavy equipment.

Q: What should I do if I take too much Celol-XT (overdose)?

Regulatory guidance on excessive intake of the Vitamin D and Calcium components emphasizes the need for immediate medical attention. Excessive intake of the medicine carries a high risk of developing dangerously high calcium levels in the blood, a condition called hypercalcemia, which can be life-threatening.

Q: What other medicines should I avoid completely while taking Celol-XT?

This medication is absolutely contraindicated, meaning it should not be taken, if you are currently taking any other Vitamin D preparations. Combining these substances significantly increases the risk of severe hypercalcemia (dangerously high blood calcium levels). Avoidance is also required if you have a pre-existing condition of high blood calcium or Vitamin D toxicity.

How should Celol-XT be stored and disposed of?

How to Store and Dispose of Celol-XT

The official storage conditions for Celol-XT (Calcitriol, Elemental Calcium, Soy Isoflavones Soft Gelatin Capsules) require strict environmental control to preserve potency.

Storage Requirements

The product must be stored in a cool, dry place, maintaining a temperature below 25°C (77°F), and protected from direct light and heat. It must remain in the original container, which should be kept firmly sealed.

Handling and Disposal

To ensure safety, Celol-XT must always be stored out of the sight and reach of children. When discarding expired or unused medicine, it must not be disposed of in household trash or via wastewater (sink or toilet). Disposal must adhere to the specific local and national regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Celol-XT found in:

A-Z Index: